Identifying disease modifying genes in multiple sclerosis

被引:100
|
作者
Kantarci, OH
de Andrade, M
Weinshenker, BG
机构
[1] Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Dept Hlth Sci Res, Rochester, MN 55905 USA
关键词
multiple sclerosis; genetics; prognosis; severity; course; outcome;
D O I
10.1016/S0165-5728(01)00481-7
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Evidence is mounting that genetic variation influences not only susceptibility to multiple sclerosis (MS), but also its course and severity. Identification of disease modifying genes, however, poses unique challenges, especially on how to classify the course and outcome of the disease in ways that may be relevant to analysis of biological factors that might be influenced by genes, The power of the statistical approaches to detect small effects of individual genes in complex disorders such as MS is problematic, and approaches to estimate power must be appropriate for the data. Nonetheless, using contemporary schemes of classification, genetic variants that influence disease course have been found; in fact, a small number have been confirmed to influence disease course in two or more independent studies. This review addresses strategies relevant to identification of disease modifying genes in MS, and summarizes and critically evaluates the cur-rent state of knowledge in this area. (C) 2002 Elsevier Science B.V All rights reserved.
引用
收藏
页码:144 / 159
页数:16
相关论文
共 50 条
  • [31] Postmarketing evidence of disease-modifying drugs in multiple sclerosis
    Trojano, Maria
    Paolicelli, Damiano
    Fuiani, Aurora
    Pellegrini, Fabio
    Iaffaldano, Pietro
    Direnzo, Vita
    D'Onghia, Mariangela
    NEUROLOGICAL SCIENCES, 2008, 29 (Suppl 2) : S225 - S226
  • [32] Multiple Sclerosis Disease-Modifying Drugs in Children and Adolescents
    Bykova O.V.
    Nankina I.A.
    Drozdova I.M.
    Kvasova O.V.
    Batysheva T.T.
    Boiko A.N.
    Neuroscience and Behavioral Physiology, 2017, 47 (5) : 544 - 552
  • [33] Effects of disease modifying treatments on cognitive dysfunction in multiple sclerosis
    Comi, Giancarlo
    NEUROLOGICAL SCIENCES, 2010, 31 : 261 - 264
  • [34] Cancer and multiple sclerosis in the era of disease-modifying treatments
    Christine Lebrun
    Patrick Vermersch
    David Brassat
    Gilles Defer
    Lucien Rumbach
    Pierre Clavelou
    Marc Debouverie
    Jérôme de Seze
    Sandrine Wiertlevsky
    Olivier Heinzlef
    Ayman Tourbah
    Agnes Fromont
    Marc Frenay
    Journal of Neurology, 2011, 258 : 1304 - 1311
  • [35] Established and novel disease-modifying treatments in multiple sclerosis
    Cross, A. H.
    Naismith, R. T.
    JOURNAL OF INTERNAL MEDICINE, 2014, 275 (04) : 350 - 363
  • [36] Regulation of human glia by multiple sclerosis disease modifying therapies
    Luke M. Healy
    Mackenzie A. Michell-Robinson
    Jack P. Antel
    Seminars in Immunopathology, 2015, 37 : 639 - 649
  • [37] Multiple sclerosis: disease modifying therapy and the human leukocyte antigen
    Werneck, Lineu Cesar
    Lorenzoni, Paulo Jose
    Kamoi Kay, Claudia Suemi
    Scola, Rosana Herminia
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2018, 76 (10) : 697 - 704
  • [38] Assessing the risk of multiple sclerosis disease-modifying therapies
    Ayrignac, Xavier
    Bilodeau, Philippe-Antoine
    Prat, Alexandre
    Girard, Marc
    Labauge, Pierre
    Le Lorier, Jacques
    Larochelle, Catherine
    Duquette, Pierre
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2019, 19 (07) : 695 - 706
  • [39] Comparing the efficacy of disease-modifying therapies in multiple sclerosis
    Mitsikostas, Dimos D.
    Goodin, Douglas S.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 18 : 109 - 116
  • [40] Postmarketing evidence of disease-modifying drugs in multiple sclerosis
    Maria Trojano
    Damiano Paolicelli
    Aurora Fuiani
    Fabio Pellegrini
    Pietro Iaffaldano
    Vita Direnzo
    Mariangela D’Onghia
    Neurological Sciences, 2008, 29 : 225 - 226